Hsia H C, Lin H C, Tsai Y T, Lee F Y, Hwang C C, Hou M C, Lee S D
Dept. of Medicine, National Yang-Ming University, Taipei, Taiwan.
Scand J Gastroenterol. 1995 Dec;30(12):1194-9. doi: 10.3109/00365529509101630.
Non-steroidal anti-inflammatory drugs (NSAIDs) often cause renal dysfunction in cirrhotic patients with ascites through inhibition of prostaglandin synthesis. However, their renal effects in cirrhotic patients without ascites are controversial. In addition, the role of prostaglandins in cirrhotic patients with ascites and in non-ascitic cirrhotic patients receiving NSAIDs also remains elusive. Thus we evaluated the chronic renal effects of indomethacin and misoprostol in 9 cirrhotic patients with ascites (protocol 1) and 21 cirrhotic patients without ascites (protocol 2).
The patients of protocol 1 received 200 micrograms of misoprostol every 6 h for 7 consecutive days. In protocol 2, 11 patients received 25 mg indomethacin three times a day for 7 consecutive days. The other 10 patients received 25 mg indomethacin three times a day plus 200 micrograms misoprostol every 6 h for 7 consecutive days. Renal function tests, plasma renin activity, and plasma aldosterone concentration were measured before and after treatment.
In protocol 1, misoprostol tended to reduce the urinary sodium excretion (p = 0.08). In protocol 2, indomethacin alone greatly impaired renal plasma flow (p < 0.05), creatinine clearance (p < 0.05), blood urea nitrogen (p < 0.05), and serum creatinine (p = 0.06) in 11 patients. Similar magnitudes of renal dysfunction were observed in the other 10 patients despite the concomitant misoprostol treatment.
Chronic administration of misoprostol may have caused a negative natriuretic effect in cirrhotic patients with ascites. In cirrhotic patients without ascites chronic administration of indomethacin may induce a renal dysfunction that cannot be reversed by misoprostol.
非甾体抗炎药(NSAIDs)常通过抑制前列腺素合成导致肝硬化腹水患者出现肾功能障碍。然而,它们对无腹水肝硬化患者的肾脏影响存在争议。此外,前列腺素在肝硬化腹水患者以及接受NSAIDs治疗的非腹水肝硬化患者中的作用也尚不明确。因此,我们评估了吲哚美辛和米索前列醇对9例肝硬化腹水患者(方案1)和21例无腹水肝硬化患者(方案2)的慢性肾脏影响。
方案1的患者连续7天每6小时服用200微克米索前列醇。在方案2中,11例患者连续7天每天服用3次25毫克吲哚美辛。另外10例患者连续7天每天服用3次25毫克吲哚美辛,同时每6小时服用200微克米索前列醇。在治疗前后测量肾功能测试、血浆肾素活性和血浆醛固酮浓度。
在方案1中,米索前列醇倾向于减少尿钠排泄(p = 0.08)。在方案2中,单独使用吲哚美辛使11例患者的肾血浆流量(p < 0.05)、肌酐清除率(p < 0.05)、血尿素氮(p < 0.05)和血清肌酐(p = 0.06)大幅受损。尽管同时使用了米索前列醇治疗,但在另外10例患者中观察到了类似程度的肾功能障碍。
慢性服用米索前列醇可能对肝硬化腹水患者产生负性利钠作用。在无腹水的肝硬化患者中,慢性服用吲哚美辛可能会诱发肾功能障碍,而米索前列醇无法逆转这种情况。